anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide the titled food or drink effective to lose the desire for drinking, by using a solution obtained by immersing raw mushroom and rootcrops, or the powder obtained by drying the solution, as an active component. CONSTITUTION:The food or drink for abstinence from wine contains the solution or its dried powder obtained by immersing raw edible mushroom (e.g. shiitake mushroom) and rootcrops (e.g. burdock) having hard tissue. For example, raw shiitake mushroom is immersed in water, preferably distilled water, and left at about 15 deg.C in dark and cold place for a whole day and night, washed and cleaned burdock is beated and crushed in the solution, and the mixture is left for 3-4 days in dark cold place. When about 50-100ml of the drink is taken usually 20min-1hr before drinking, the taste of wine becomes unagreeable, and the desire for drinking declines to achieve the abstinence from wine successfully.
AIM: In Japan, Niraparib maintenance therapy for primary and recurrent ovarian cancer was approved in September 2020 and is expected to improve the prognosis of ovarian cancer. However, the safety of niraparib maintenance therapy in Japanese patients has not been fully evaluated.
METHODS: Patients with ovarian cancer (including fallopian tube and peritoneal cancer) treated with niraparib at Jichi Medical University Hospital from September 2020 to August 2022 were enrolled in this study. Patient background, starting dose, rates of interruption, reduction, or discontinuation, adverse events (AEs) during treatment, and estimated glomerular filtration rate (eGFR) trends were retrospectively analyzed.
RESULTS: Twenty-nine patients received niraparib maintenance therapy during the study period, including 21 with primary cancer and 8 patients with recurrent cancer. Seventeen patients (58.6%) required dose interruptions and 16 patients (55.2%) required dose reductions. Only two patients (6.9%) discontinued treatment due to fatigue and nausea. The most frequent AE was creatinine increases in 18 patients (62.1%, all grades). Although eGFR levels decreased significantly after niraparib therapy compared to before niraparib therapy (59.3 vs. 50.3 mL/min/1.73 m2 , p < 0.001), the levels returned to pre-niraparib initiation levels after discontinuation of niraparib (64.6 vs. 64.6 mL/min/1.73 m2 , p = 0.96). Multivariate regression analysis showed that diabetes was independently associated with decreased eGFR (p = 0.013).
CONCLUSIONS: Niraparib maintenance therapy frequently increased serum creatinine, but the change was reversible. Further studies are needed to determine the effects of niraparib on renal function in Japanese patients.
Patients receive oral sulindac and oral tamoxifen citrate twice daily for up to 12 months (four 3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 1 additional month of treatment beyond documentation of CR.
The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
The invention relates to a drug for reducing blood glucose, regulating blood lipid and treating diabetes mellitus combined with hyperlipidemia and other chronic vascular complications and a preparation method thereof. The drug is total alkaloids which are extracted from traditional Chinese medicine golden thread. The preparation method of the drug comprises the following steps: 1) the golden thread herbal medicine is crushed into coarse powder; 2) 5-10 times of the amount of 60-80 percent ethanol is used for carrying out the reflux extraction of the golden thread coarse powder for 1-3 times by 1-2h/time, the filtration is carried out by times, and filtrates are merged. Golden thread extract is obtained by pressure reduction concentration and drying; 3) the golden thread extract is added in 5 times of the amount of 0.5 percent sulfuric acid for dissolution and filtration, the filtrates are respectively regulated to pH9 by lime milk, filtrated and respectively regulated to pH1-2 by hydrochloric acid, sodium chloride is added to allow the salt content to be 10 percent, and the total alkaloids of the golden thread are obtained by even shaking and still placement. Or the golden thread extract is used for separating and purifying the total alkaloids of the golden thread by macroporous resin method. The drying is carried out, and the total alkaloids of the golden thread are prepared into oral formulation or injection formulation. The drug has prominent efficacy for the diabetes mellitus combined with hyperlipidemia and other chronic vascular complications.
The present invention provides a composition with nerve-soothing effects, which is prepared by mixing, in suitable proportions, Arundo donax, Mimosa pudica L., Cordyline fruticose (L.) Goepp., Polygonum cuspidatum Sieb. Et Zucc., Gardenia jasminoides Ellis, Leueaena leucocephala (Lam.) de Wit, Lonicera japonica Thunb., Lagerstroemia subcostata, Portulaca oleracea L., Tabernaemontana divaricate (L) R. Br. Ex Roem. & Schult.; naturally drying t    he mixture; grinding the mixture into powder/particles; and extracting and mixing the powder/particles to form a composition containing natural extracts. The composition has the properties and effects of ingredients contained therein and has the functions of nerve soothing, relaxing emotion, aiding sleep, relieving pressure, relieving uncomfortable mood, and assisting in settling nerves, thereby improving the quality of sleep and effectively rectifying sleep disorder.
They will receive weekly information on parenting in the 1st year of life. They will have direct contact (via WhatsApp) with a child psychologist to ask questions about the material and to refer to specialized support if needed.
Parental decision-making for children with advanced cancer is complex. Many parents have overly optimistic beliefs about prognosis and as a result choose aggressive measures even at the end of life, which are associated with greater suffering. Yet most parents wish to limit suffering, and in retrospect, many regret choices for cancer treatment for advanced cancer. These findings suggest that parents do not always have the information they need to make decisions that reflect their preferences.

The proposed study will evaluate parental decision-making in advanced cancer, addressing gaps in the literature in 3 important respects. 1) Previous work on decision-making for children with advanced cancer has typically looked at decisions at one point in time, often asking parents to reflect on decisions after the child's death, even though parents' understanding of prognosis and decisions about care evolve over time. We will evaluate parental decision-making for advanced cancer over time. 2) Existing work focuses on aggressive end-of-life care as the worst possible outcome. However, some parents wish to pursue aggressive measures even when they recognize that the child has little chance for cure. We will evaluate the extent to which parental decision-making for advanced cancer is informed and consonant with preferences, regardless of whether decisions lead to aggressive or palliative care. 3) Previous studies have focused on groups of different childhood cancers, making it difficult to ascertain whether differences in decision-making reflect differences in diseases, options for care, or parent preferences. We will focus on a single disease, relapsed neuroblastoma, as a model for parental decision-making. Children with relapsed neuroblastoma have advanced cancer but many options for care, including established cancer regimens, clinical trials, and palliation. Relapsed neuroblastoma presents an ideal model for parental decision-making in the setting of a complex array of choices. We will follow 120 parents at 8 institutions over time, beginning at relapse and continuing over 18 months. Parent interviews every 3 months and reviews of medical records throughout that time will be used to evaluate the ways that parental preferences for the aggressiveness of treatment change over time (Aim 1). Parental perception that care has been burdensome will be evaluated as possible driver of change in decision-making (Aim 2). Ideally, parent values for care would be the primary driver of treatment goals. Thus we will evaluate the extent to which parental understanding of prognosis, treatment options, and expected benefits and burdens of treatment can allow decision-making consonant with parental preferences in the absence of prior negative experiences with care (Aim 3). Finally, in-depth parent interviews will allow us to evaluate personal factors that drive parental decision-making (Aim 4). Throughout the study, a Parent Advisory Group will guide assessment of care preferences and decision-making.
The invention discloses a medicine for tonifying the kidney, protecting calcium and preventing osteoporosis and a preparation process thereof. The medicine is prepared from 5-60wt% of a tuber fleeceflower root polysaccharide, 10-60wt% of a fructificatio flammulinae velutipis polysaccharide, 10-45wt% of a scarlet caterpillar fungus polysaccharide, 5-20wt% of a rhizoma dioscoreae polysaccharide and 5-10wt% of an agaricus blazei polysaccharide. The preparation process of the medicine comprises the following steps: culturing, filtering, purifying, drying, smashing, compounding, and filling. The medicine is a medicable health food, has no side and toxic effects and is suitable for people needing to tonify the kidney, protect calcium and prevent osteoporosis. In addition, the medicine has the efficacies of tonifying and protecting the liver and the kidney, replenishing essence, blood and marrow, blackening beard and hair, strengthening bones and muscles, reducing phlegm, stopping phthisical cough, reinforcing the intestines and the stomach and resisting cancers. 1 to 2 granules needs to be taken by an ordinary adult each time for 2 to 3 times a day, and the medicine can be taken for a long time.
Sound Ear Check (SEC) is an automated tablet-based self-test that uses common nonspeech sounds (ecological sounds) that are accompanied by pictures that are easily recognizable even for younger children.

Before TTI operation, each participant will be tested with SEC using normal (dichotic) sounds and antiphasic sounds. Results will be compared to middle ear findings and the test will be repeated one month after the operation when the middle ears are checked to be dry (with a ventilation tube). At the time of the myringotomy during TTI operation, possible middle ear fluid will be classified as serous (transparent, clear), mucous (thick) or purulent (consisting of pus). A tympanometry will be performed within the same visit as the SEC measurement before the TTI operation. At the time of tympanometric examination, each participant will be classified as cooperative (sittings still, not crying, not resisting) or non-cooperative. Tympanometric findings will be classified after the Jerger classification. SEC and tympanometric testing is designed to be performed at the same visit as TTI operation as patients will be waiting for the operation at the ward. Medical history of the study patients will be collected from the hospital patient records and through interview and questionnaires to the subjects. Ear related quality of life questionnaire (OM-6) will be performed at the beginning of the study and the one month control visit. Questionnaires are collected using web-based REDCap -software (Research Electronic Data Capture).
The present invention discloses the PA1-3F10 monoclonal antibody and a hybridoma cell line producing it. The antibody is shown to bind to a variety of carcinomas and malignant cells with haematopoietic origin with a high intensity and degree of selectivity as demonstrated by immunohistochemistry analysis and cell binding assays. The invention also includes antibodies having substantially the same binding specificity as the monoclonal antibody PA1-3F10, and mutants, derivatives, functional equivalents or fragments of the antibody. Applications of the antibodies include the therapy or diagnosis of cancer, e.g. in targetting cytotoxic compounds to cancer cells. In particular, the present invention relates to cancer therapy and diagnosis of colorectal cancer.
PURPOSE: To analyze sac evolution patterns in matched patients with hostile neck anatomy (HNA) treated with standard endovascular aneurysm repair (sEVAR) and endosutured aneurysm repair (ESAR).
METHODS: Observational retrospective study using prospectively collected data between June 2010 and December 2019. ESAR group data were extracted from the primary arm of the PERU registry with an assigned identifier (NCT04100499) at 8 centers and those from the sEVAR came from 4 centers. Suitability for inclusion required: no proximal endograft adjuncts (besides EndoAnchor use), ≤15 mm neck length and minimum of 12-months follow-up imaging. Bubble-shaped neck (noncylindrical short neck with discontinuous seal) aspect was analyzed. Both groups were analyzed using propensity score matching (PSM) for aortic neck length, width, angulation, and device fixation type. Main outcome assessed was sac evolution patterns (sac expansion and regression were defined as >5mm increase or decrease, of the maximum sac diameter respectively; all AAAs within this ±5 mm range in diameter change were considered stable) and secondary outcomes were type-Ia endoleaks; other endoleaks and mortality. A power analysis calculation >80% was confirmed for sac regression evaluation.
RESULTS: After exclusions, PSM resulted in 96 ESAR and 96 sEVAR patients. Mean imaging follow-up (months) was 44.4±21.3 versus 43.0±19.6 (p=0.643), respectively. The overall number of patients achieving sac regression was higher in the ESAR group (n=57, 59.4% vs n=31, 32.3%; p<0.001) and the cumulative sac regression achieved at 5 years was 65% versus 38% (p=0.003) in favor of the ESAR group. There were no statistically significant differences in type-Ia endoleak and/or other endoleaks. Univariate analysis for sac regression patients in the sEVAR and ESAR group individually showed the bubble-shape neck as a predictor of sac regression failure. There were no statistical differences in overall and aneurysm-related mortality.
CONCLUSION: Endosutured aneurysm repair provided improved rates of sac regression for patients with AAA and HNA when compared with sEVAR at midterm and up to 5 years, despite similar rates of type-Ia endoleaks, and the need to consider some important limitations. The presence of bubble-shaped neck was a predictor of sac regression failure for both groups equally.
CLINICAL IMPACT: The use of EndoAnchors aids and improves EVAR treatment in hostile neck anatomies by an increased rate of sac regression when compared to EVAR treatment alone in up to 5 year analysis. Moreover, a trend to reduced number of type Ia endoleaks is also achieved, although not significant in the present study. This data, adds to current and growing evidence on the usefulness of EndoAnchors for AAA endovascular treatment.
BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
The present application discloses a process for the purification of a neutral human milk 5 oligosaccharide (neutral HMO). The process uses simulated moving bed (SMB) chromatography which allows the continuous purification of large quantities of HMOs with high purity. Contrary to chemical synthesis routes of neutral HMOs, and their subsequent purification, the presented process allows the provision of HMOs free of noxious chemicals, such as e.g. trace amounts of heavy metals or organic solvents. The 10 individual neutral HMO product may be obtained in solid form by spray drying or as a concentrated syrup. The provided neutral HMO is very well-suited for use in food applications. WO 2015/049331 PCT/EP2O1-4/071145 Figure 1 1 v
The invention relates to the field of natural traditional Chinese medicine protein, and more particularly relates to Angelica Sinensis Protein (ASPR) and a protein self-assembly nanoparticle thereof, wherein the N-terminal sequence of the protein is GIQKTEVEAPSTVSA. The ASPR protein can be self-assembled to form nanoparticles by heating at 100 ℃ for 15min under the condition of pH 8.0. The average particle size of the protein self-assembly nano-particles ASPR-NP separated by 100KDa ultrafiltration is 154.9 +/-27.2 nm. The nanoparticle has good stability, and can enter cells through a membrane and reach mitochondria. In addition, the ASPR can embed small molecule insoluble drug Ferulic Acid (FA) to obtain ASPR-FA-NP with average particle size of 216.3 + -18.3 nm. The ASPR-FA-NP has good stability, can selectively promote the proliferation of normal liver cells and inhibit the proliferation of liver cancer cells, and has good biocompatibility.
NEW MATERIAL:Plasminogen activator KYM produced by the mutant KYM-A of human rhabdomyosarcoma cell. Appearance, white powder; molecular weight, two bands between 56,000 and 62,000 (nonreduced type) and between 32,000 and 36,000 (reduced type) by SDS-polyacrylamide gel electrophoresis; solubility, 50mug/ ml in water and salt solution, insoluble in ethanol and ether. USE:Thrombolytic agent. It is a weakly basic glycoprotein having stronger fibrin- bonding capability than urokinase. It is prepared preferably in the form administrable by intravenous injection. PREPARATION:The cell KYM-I separated from human rhabdomyosarcoma (presented by Dr. Morimasa Sekiguchi, Medical Science Laboratory, Tokyo University) is cultured, and the mutant KYM-A prepared by the repeated separation, selection and culture of the cell is subjected to the suspension culture under agitation to obtain the titled substance on an industrial scale.
PURPOSE:To treat infections diseases in immunodeficient hosts having various basic diseases, by using a granulocytic colony stimulating factor (G-CSF) and an antimicrobial agent together. CONSTITUTION:A granulocytic colony stimulating factor (G-CSF) is administered to a patient in which a leukopenic state or leukopenia is predicted or patient after onset of an infections disease in 0.1-500mug, preferably 0.5-200mug dose and then an antimicrobial agent is administered. Human G-CSF having the following physico-chemical properties, etc., is preferred. Molecular weight; 19,000+ or -1,000 measured by sodium dodecyl sulfate (SDS)-polyacrylamide electrophoresis. Isoelectric point; At least one of 5.5+ or -0.1, 5.8+ or -0.1 and 6.0+ or -0.1. Ultraviolet absorption characteristics; Maximum absorption at 280nm and minimum absorption at 250nm. Amino acid sequence to a residue at the 21st position from the N-terminal; Sequence indicated by the formula. Severe infections diseases which have hereto for been difficult to cure can be healed by the combined used of the G-CSF.
Absorption/Bioavailability

CMI from clomipramine hydrochloride capsules is as bioavailable as CMI from a solution. The bioavailability of CMI from capsules is not significantly affected by food.

In a dose proportionality study involving multiple CMI doses, steady-state plasma concentrations (Css) and area-under-plasma-concentration-time curves (AUC) of CMI and CMI's major active metabolite, desmethylclomipramine (DMI), were not proportional to dose over the ranges evaluated, i.e., between 25 to 100 mg/day and between 25 to 150 mg/day, although Css and AUC are approximately linearly related to dose between 100 to 150 mg/day. The relationship between dose and CMI/DMI concentrations at higher daily doses has not been systematically assessed, but if there is significant dose dependency at doses above 150 mg/day, there is the potential for dramatically higher Css and AUC even for patients dosed within the recommended range. This may pose a potential risk to some patients (see WARNINGS and PRECAUTIONS, Drug Interactions). After a single 50 mg oral dose, maximum plasma concentrations of CMI occur within 2 to 6 hours (mean, 4.7 hr) and range from 56 ng/mL to 154 ng/mL (mean, 92 ng/mL). After multiple daily doses of 150 mg of clomipramine hydrochloride capsules, steady-state maximum plasma concentrations range from 94 ng/mL to 339 ng/mL (mean, 218 ng/mL) for CMI and from 134 ng/mL to 532 ng/mL (mean, 274 ng/mL) for DMI. Additional information from a rising dose study of doses up to 250 mg suggests that DMI may exhibit nonlinear pharmacokinetics over the usual dosing range. At a dose of clomipramine hydrochloride capsules 200 mg, subjects who had a single blood sample taken approximately 9 to 22 hours, (median 16 hours), after the dose had plasma concentrations of up to 605 ng/mL for CMI, 781 ng/mL for DMI, and 1386 ng/mL for both.
A controlled substance distribution system may include a controlling entity having a database. The database may include data associated with a patient, an amount of a controlled substance that the patient is authorized to receive, and an amount of the controlled substance that the patient has already received during a time period. The system may include a token having a unique identifier. The data may include data that is associated with the unique identifier. The system may include a dispensing center having a computing device in communication with the controlling entity. The computing device may be configured to obtain the unique identifier from the token, transmit the unique identifier and a request for the controlled substance to the controlling entity, receive an indication of whether or not the request is allowed, and authorize a dispensing event in response to the request if the indication indicates that the request is allowed.
PURPOSE: A composition containing a compound for preventing or treating liver disease due to alcohol is provided to reduce GOT and GPT level. CONSTITUTION: A composition for preventing or treating liver disease due to alcohol contains a compound of general formula I(S-(MS)_p-(MS)_q) as an active ingredient. In general formula I, S is sialic acid; and (MS)_p and (MS)q are independently monosaccharide residue. (MS)_p is galactose and (MS)_q is glucose. The liver disease is alcoholic fatty liver, alcoholic hepatitis, alcoholic cirrhosis, or alcoholic liver cancer. The composition is a pharmaceutical composition, neutraceutical composition, or food composition.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to phthisiology, pulmonology, thoracic surgery. Method includes standard anti-tuberculosis treatment. Into pleural cavity, without extraction of pleural fluid introduced is mixture of medications, consisting of 10 thousand units of contrical, 5 thousand units of heparin and 30 mg of prednisolone at the background of standard antibacterial treatment. Introduction of medication mixture is carried out on 5-6 ml of pleural fluid. If treatment of pleurisy is started in due time, mixture is introduced single time, in case of total, chronic or recurring pleurisy mixture is introduced 2-3 times with 7-10 day intervals. ^ EFFECT: method ensures reduction of disease treatment terms, due to efficient elimination of inflammation and prevention of immunodeficient state caused by loss of protein substances, contained in pleural fluid, is economical and non-burdensome either for patient or for physician. ^ 2 ex